237 related articles for article (PubMed ID: 30308586)
1. Prasugrel versus clopidogrel for residual thrombus burden in patients with ST-segment elevation myocardial infarction: an optical coherence tomography study.
Yokota T; Higuma T; Endo T; Nishizaki F; Hanada K; Yokoyama H; Yamada M; Okumura K; Tomita H
Coron Artery Dis; 2018 Dec; 29(8):663-669. PubMed ID: 30308586
[TBL] [Abstract][Full Text] [Related]
2. Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction.
Di Vito L; Versaci F; Limbruno U; Pawlowski T; Gatto L; Romagnoli E; Cattabiani MA; Micari A; Trivisonno A; Marco V; Prati F
J Cardiovasc Med (Hagerstown); 2016 Sep; 17(9):701-6. PubMed ID: 27467458
[TBL] [Abstract][Full Text] [Related]
3. Reloading When Switching From Ticagrelor or Prasugrel to Clopidogrel Within 7 Days After STEMI.
Claassens DMF; Tavenier AH; Hermanides RS; Vos GJA; Hinrichs DL; Bergmeijer TO; van 't Hof AWJ; Deneer VHM; Ten Berg JM
JACC Cardiovasc Interv; 2020 Mar; 13(5):663-665. PubMed ID: 32139231
[No Abstract] [Full Text] [Related]
4. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
[TBL] [Abstract][Full Text] [Related]
5. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
Akita K; Inohara T; Yamaji K; Kohsaka S; Numasawa Y; Ishii H; Amano T; Kadota K; Nakamura M; Maekawa Y
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):231-238. PubMed ID: 31593213
[TBL] [Abstract][Full Text] [Related]
6. Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis).
Valenti R; Marcucci R; Comito V; Marrani M; Cantini G; Migliorini A; Parodi G; Gensini GF; Abbate R; Antoniucci D
JACC Cardiovasc Interv; 2015 Oct; 8(12):1563-70. PubMed ID: 26386764
[TBL] [Abstract][Full Text] [Related]
7. Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study.
Mont'Alverne-Filho JR; Rodrigues-Sobrinho CR; Medeiros F; Falcão FC; Falcão JL; Silva RC; Croce KJ; Nicolau JC; Valgimigli M; Serruys PW; Lemos PA
Catheter Cardiovasc Interv; 2016 Jun; 87(7):1187-93. PubMed ID: 26614123
[TBL] [Abstract][Full Text] [Related]
8. Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study.
Hulot JS; Chevalier B; Belle L; Cayla G; Khalife K; Funck F; Berthier R; Piot C; Tafflet M; Montalescot G;
JACC Cardiovasc Interv; 2020 Mar; 13(5):621-630. PubMed ID: 32139220
[TBL] [Abstract][Full Text] [Related]
9. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.
Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Claassens DMF; Ten Berg JM; Asselbergs FW; Al-Ali AK
BMC Cardiovasc Disord; 2020 Jun; 20(1):268. PubMed ID: 32493215
[TBL] [Abstract][Full Text] [Related]
10. Reduction of in-stent thrombus immediately after percutaneous coronary intervention by pretreatment with prasugrel compared with clopidogrel: An optical coherence tomography study.
Kubo T; Ino Y; Matsuo Y; Shiono Y; Kameyama T; Yamano T; Katayama Y; Taruya A; Nishiguchi T; Satogami K; Kashiyama K; Orii M; Kuroi A; Yamaguchi T; Tanaka A; Hozumi T; Akasaka T
J Cardiol; 2017 Feb; 69(2):436-441. PubMed ID: 27160709
[TBL] [Abstract][Full Text] [Related]
11. The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study.
Effron MB; Wang TY; Fonarow GC; Henry TD; Zettler ME; Baker BA; McCoy LA; Peterson ED
Catheter Cardiovasc Interv; 2018 Feb; 91(2):242-250. PubMed ID: 28988425
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction.
Flierl U; Zauner F; Sieweke JT; Berliner C; Napp LC; Tillmanns J; Bauersachs J; Schäfer A
Thromb Haemost; 2017 Jan; 117(1):99-104. PubMed ID: 27734075
[TBL] [Abstract][Full Text] [Related]
13. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
[TBL] [Abstract][Full Text] [Related]
15. Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis.
Bundhun PK; Huang F
BMC Cardiovasc Disord; 2018 May; 18(1):78. PubMed ID: 29720092
[TBL] [Abstract][Full Text] [Related]
16. The relationship between timing of prasugrel pretreatment and in-stent thrombus immediately after percutaneous coronary intervention for acute coronary syndrome: an optical coherence tomography study.
Katayama Y; Kubo T; Ino Y; Kameyama T; Matsuo Y; Kitabata H; Terada K; Emori H; Aoki H; Taruya A; Shimamura K; Ota S; Tanaka A; Hozumi T; Akasaka T
Heart Vessels; 2018 Oct; 33(10):1159-1167. PubMed ID: 29691643
[TBL] [Abstract][Full Text] [Related]
17. Does Residual Thrombus After Aspiration Thrombectomy Affect the Outcome of Primary PCI in Patients With ST-Segment Elevation Myocardial Infarction?: An Optical Coherence Tomography Study.
Higuma T; Soeda T; Yamada M; Yokota T; Yokoyama H; Izumiyama K; Nishizaki F; Minami Y; Xing L; Yamamoto E; Lee H; Okumura K; Jang IK
JACC Cardiovasc Interv; 2016 Oct; 9(19):2002-2011. PubMed ID: 27712735
[TBL] [Abstract][Full Text] [Related]
18. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
[TBL] [Abstract][Full Text] [Related]
19. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
[TBL] [Abstract][Full Text] [Related]
20. Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry.
Lupi A; Bona RD; Meliga E; Capodanno D; Schaffer A; Bongo AS; Gaudio G; Guasti L; Alexopoulos D; Valgimigli M; Porto I
Thromb Haemost; 2018 May; 118(5):852-863. PubMed ID: 29618159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
